L3VLUP
ProSign in

CRVS in the 13F filings

Corvus Pharmaceuticals Inc · CUSIP 221015100

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q3 2025Q2 2025Q3 2024Q1 2023Q4 2022Q1 2017
Quarter end
31 Mar 2017
the date the book describes
Filed
15 May 2017
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
83
filed both Q4 2016 and Q1 2017; 0 listed it in both
Shares listed
408,277
combined, among listed positions
Reported value
$8.5m
combined, at the quarter end

Managers listing CRVS in Q1 2017

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2016, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Point72 Asset Management LP408,277$8.5munder 0.1%Newnew15 May 2017 (the filing on sec.gov)

Largest increases and reductions, by shares

There is no earlier quarter on file to compare with.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q1 2017 to 1 in Q2 2026

Tracked managers listing it, at least.

00111Q1 2017Q4 2022Q1 2023Q3 2024Q2 2025Q3 2025Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
CRVS by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20171$8.5mn.a.n.a.
Q4 20221$466kn.a.n.a.
Q1 20231$499kn.a.n.a.
Q3 20241$29m01
Q2 20251$28m10
Q3 20251$48m01
Q1 20261$2.5m168
Q2 20261$3.7m1011

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

CRVS and LLY →CRVS and JNJ →CRVS and VRTX →Choose a stock to compare with CRVS →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own CRVS, latest filings →Back to the 13F Explorer →